Dofetilide Capsule
Product Images NDC 70518-4617

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dofetilide (NDC 70518-4617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Dofetilide 250mcg(0.25mg) 70518 4617 00)

This text provides information about Dofetilide capsules, each containing 250mcg (0.25mg) in a box of 50. It includes details like the NDC number, packaging details, manufacturer information (Novadoz Pharmaceuticals LLC), storage conditions, and a reminder to keep the medication out of children's reach. The text also mentions the need to protect the capsules from moisture and humidity and provides contact information for RemedyRepack Inc. for repackaging. Regular dosage instructions are advised to be checked in the insert.*

FDA Label Image

Mm2 (Dofetilide 250mcg(0.25mg) 70518 4617 01)

This text provides information about Dofetilide capsules in the dosage of 250mcg (0.25mg). It includes details such as the quantity, NDC number, lot number, expiration date, and manufacturer information (Novadoz Pharmaceuticals LLC). The capsules are meant to be stored at a temperature range of 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Instructions to protect it from moisture and humidity are also mentioned, along with the advice to keep it out of reach of children. Additionally, it indicates that the usual dosage information can be found in the insert. The capsules have been repackaged by RemedyRepack Inc. in Indiana.*

FDA Label Image

Gualt-eq (Dofetilide Capsules Gault Eq)

This text provides instructions for managing a patient's medication, dofetilide, based on factors such as baseline QTc or QT intervals, creatinine clearance (Clcr), and post-dose adjustments. It outlines dosing recommendations, contraindications, and criteria to consider when adjusting or discontinuing the medication. The guidelines aim to optimize patient safety and treatment efficacy.*

FDA Label Image

Fig01 (Dofetilide Figure 01)

FDA Label Image

Fig02 (Dofetilide Figure 02)

FDA Label Image

Fig-03 (Dofetilide Figure 03)

This text seems to provide information on the probability of remaining in normal sinus rhythm (NSR) based on different dosage levels of Falve Log Rark being administered at various time intervals (125 mg BID, 250 mg 8D, and 50 mg 81D). It mentions the corresponding probabilities (p values) associated with each dosage regimen. The data is potentially part of a study or research related to the effectiveness of Falve Log Rark in maintaining NSR over time.*

FDA Label Image

Fig-04 (Dofetilide Figure 04)

FDA Label Image

Struct (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.